Replies to post #126648 on Biotech Values

[NP1986]

From Shkreli's twitter account:

EXEL drops dose in clinical trial - this is a disaster - stock should be down 20%

this is their only product and evidently the dose they planned is too toxic to give. ~$1bn market cap and their only product. ruh oh

more $EXEL... from what i've seen the company has gone from 100 to 60 to 40mg due to tox. the therapeutic index is probably best at 0mg.

Subtle.